STAT3-IN-18_product_DataBase

Bioactivity	STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.
Invitro	STAT3-IN-18 (0.5 μM; 48 h) 在 MDA-MB-231 细胞中，抑制 STAT3 和 JAK2 的磷酸化，降低 Bcl-2 和 COX-2 的蛋白水平，增加 Bak、Caspase-3、Cleaved-PARP1 的蛋白水平[1]。STAT3-IN-18 (0.5 μM; 36 h) 将 MDA-MB-231 细胞的细胞周期阻滞在 S 期，(0.5 μM; 48 h) 并诱导细胞凋亡。 0 --> STAT3-IN-18 相关抗体:
In Vivo	STAT3-IN-18 (相当于 1.5 mg Pt；2 天一次，共 18 天) 在 4T1 异种移植瘤小鼠模型中抑制 STAT3 磷酸化，抑制肿瘤生长。STAT3-IN-18 的中位致死剂量 (LD50) 为 10.45 mg/kg[1]。
Name	STAT3-IN-18
CAS	2668267-41-0
Formula	C18H24Cl2N2O6Pt
Molar Mass	630.38
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Cai L, Wang Y, Chen H, Tan Y, Yang T, Zhang S, Guo Z, Wang X. Platinum(IV) Complexes as Inhibitors of STAT3 and Regulators of the Tumor Microenvironment To Control Breast Cancer. J Med Chem. 2023 Aug 24;66(16):11351-11364.

PeptideDB